A numbers guide to why Novartis, Lilly, and Roche may each be cornered into buying Arrowhead, how high each could rationally bid, and where the thesis could break
I note that Biogen are releasing P2 data for their Tau targeting ASO at the forthcoming AAIC meeting. There may be some (albeit limited) read through to the Arrowhead asset.
I note that Biogen are releasing P2 data for their Tau targeting ASO at the forthcoming AAIC meeting. There may be some (albeit limited) read through to the Arrowhead asset.